Join the 'Fludrocortisone' group to help and get support from people like you.
Posted 3 Aug 2017 by Drugs.com
WEDNESDAY, Aug. 2, 2017 – The U.S. Food and Drug Administration on Wednesday expanded approval for the anti-cancer drug Imbruvica (ibrutinib) to include adults with chronic graft versus host disease (cGVHD). cGVHD is a deadly condition that affects up to 70 percent of people who receive a stem cell transplant to treat cancers of the blood or bone marrow, the FDA said in a news release. The...